Engineered Exosome-based Drug Delivery System for Synergistic Cancer Therapy

August 17, 2024 01:00 AM AEST | By EIN Presswire
 Engineered Exosome-based Drug Delivery System for Synergistic Cancer Therapy
Image source: EIN Presswire

USA, August 16, 2024 /EINPresswire.com/ -- The researchers developed an exosome-based drug delivery system which employed synergistic miRNA-based autophagy inhibition and 7-coumarin-based chemotherapy for ovarian cancer therapy.

Ovarian cancer is one of the most common malignancies in women worldwide. Unlike breast cancer, ovarian cancer lacks early diagnostic markers and does not show noticeable symptoms until cancer metastases, leading to a low survival rate for ovarian cancer patients. Traditional cancer treatments include surgery, radiation therapy, chemotherapy and interventional therapy. However, the distribution of chemotherapeutic drugs in vivo is non-specific and often toxic to healthy cells, leading to unsatisfactory efficacy.

In a study (https://doi.org/10.1016/j.bioana.2024.05.002) published in the KeAi journal Biomedical Analysis, a group of researchers from China outline a new discrimination and treatment approach — a novel exosome-based drug delivery system that could improve the cell entry ability of drugs and the targeting of cancer cells. This approach provides a new drug delivery system and synergistic therapy idea, paving the way for future clinical applications.

"Exosomes are extracellular vesicles with lipid bilayers that have been extensively used as delivery vehicles for multiple drugs due to their high biocompatibility, low immunogenicity, the abilities to cross various biological barriers and evade the clearance by immune system," explains the study's corresponding author Songqin Liu, a professor at the Jiangsu Engineering Laboratory of Smart Carbon-Rich Materials and Device at Southeast University. "The synergistic cancer treatment by loading various nucleic acids and drugs into exosomes utilizes the advantages of different therapeutic approaches and has been applied to effectively treat cancers through the synergy of different treatment mechanisms."

Autophagy is an intracellular degradative process where a cell engulfs its own cytoplasmic proteins or organelles and encapsulates them into autophagosomes. Many studies have shown that in cancer biology, autophagy plays a dual role in tumor promotion and inhibition. Notably, inhibition of autophagy shows potential in improving the clinical treatment of cancer patients.

"We constructed a novel antitumor exosome-based drug delivery system employing the synergistic effects of miRNA-regulated autophagy inhibition and coumarin anticancer drugs to achieve effective treatment of ovarian cancer,” says Xin Hua, first author of the study. "With the anti-tumor effects and intracellular visualization from 7-coumarin, the regulation of the autophagy process from encapsulated miRNA, the targeting of cancer cells from exosome, the synergistic effect and exosome-based drug delivery strategy for anti-cancer therapy showed promising prospects for in vitro and clinical applications."

DOI
10.1016/j.bioana.2024.05.002

Original Source URL
https://doi.org/10.1016/j.bioana.2024.05.002

Funding information
This project was supported by the ZhiShan Scholar Program of Southeast University (2242022R40053).

Lucy Wang
BioDesign Research
email us here


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.